NEWARK, DE | The biomarker-based immunoassays market was valued at USD 5.4 billion in 2025 and is projected to reach USD 9.63 billion by 2036, expanding at a steady CAGR of 5.4%. This growth reflects a strategic shift in diagnostics toward precision quantitation of disease-specific biomarkers, enabling earlier intervention in high-mortality conditions such as oncology and neurology....